Uganda NDA appoints Rogers Kayita as new Corporate Services Director

• The National Drug Authority has appointed Rogers Kayita as its new Director of Corporate Services to strengthen corporate governance practices.
• The new director brings extensive experience in corporate law and governance from previous roles at leading Ugandan companies.
• The NDA's regulatory framework is now governed by the National Drug and Health Products Authority Act, 2025, which replaced the previous Act in March 2026.
• Pharmaceutical companies operating in Uganda must be prepared to adapt to changing regulatory requirements under the NDA's strengthened oversight.
• Lawyers advising these companies should closely monitor developments related to the Directorate's role and responsibilities.

The appointment comes as part of the NDA's broader strategy to enhance its oversight and enforcement capabilities in the pharmaceutical sector.

The National Drug Authority (NDA) has appointed Rogers Kayita as its new Director of Corporate Services, marking a significant development in the regulatory body's efforts to strengthen its corporate governance practices. The appointment comes as part of the NDA's broader strategy to enhance its oversight and enforcement capabilities in the pharmaceutical sector. According to sources, the new director brings extensive experience in corporate law and governance, having previously worked with several leading companies in Uganda. This move is seen as a major step towards improving the NDA's ability to effectively regulate the industry and protect public health.

The National Drug Authority operates under the umbrella of the Ministry of Health, with its primary mandate being to ensure the quality and safety of pharmaceutical products in Uganda. The NDA's regulatory powers are now derived from the National Drug and Health Products Authority Act, 2025, which replaced the outdated National Drug Policy and Authority Act of 1993 (Cap 206) in March 2026. As a key player in the regulation of the pharmaceutical sector, the NDA plays a critical role in safeguarding public health by enforcing compliance with international standards and best practices. The appointment of a new Director of Corporate Services is expected to bolster the NDA's capacity to discharge its regulatory responsibilities effectively.

The appointment of a new Director of Corporate Services at the National Drug Authority has significant implications for pharmaceutical companies operating in Uganda. As the NDA continues to strengthen its corporate governance practices, companies must be prepared to adapt to changing regulatory requirements. Lawyers advising these companies should closely monitor developments related to the Directorate's role and responsibilities, as updates on corporate governance practices may impact their clients' operations in the country. Furthermore, this move underscores the importance of effective regulation in ensuring public health and safety, highlighting the need for pharmaceutical companies to prioritize compliance with international standards and best practices.

Lawyers should watch for updates on the Directorate's role and responsibilities, as changes to corporate governance practices may impact pharmaceutical companies operating in Uganda.

Source: Original reporting via Briefly